GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (STU:CXF) » Definitions » EPS (Basic)

Chimerix (STU:CXF) EPS (Basic) : €-0.87 (TTM As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Chimerix EPS (Basic)?

Chimerix's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was €-0.23. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.87.

Chimerix's EPS (Diluted) for the three months ended in Sep. 2024 was €-0.23. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.87.

Chimerix's EPS without NRI for the three months ended in Sep. 2024 was €-0.23. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -0.87.

During the past 3 years, the average EPS without NRI Growth Rate was -9.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 7.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 13.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Chimerix's highest 3-Year average EPS without NRI Growth Rate was 22.60% per year. The lowest was -91.50% per year. And the median was 9.40% per year.


Chimerix EPS (Basic) Historical Data

The historical data trend for Chimerix's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimerix EPS (Basic) Chart

Chimerix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.83 -0.58 -1.81 1.86 -0.85

Chimerix Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.25 -0.19 -0.23 -0.21 -0.23

Chimerix EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Chimerix's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-75.281-0)/88.604
=-0.85

Chimerix's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-20.614-0)/89.701
=-0.23

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chimerix  (STU:CXF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Chimerix EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Chimerix's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimerix Business Description

Traded in Other Exchanges
Address
2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.

Chimerix Headlines

No Headlines